ELAN Pengajuan SEC - Elanco Animal Health Incorporated- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300SHPNDCE059M934
CIK	1739104

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Elanco Animal Health Incorporated

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 7, 2025	EX-99.1	Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2025 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target •Second Quarter 2025 Financial Results: ◦Revenue of $1
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Elanco Animal Heal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (
June 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 25, 2025 Elanco Animal Heal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 25, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co
June 26, 2025	EX-10.1	First Amendment to Receivables Loan Agreement by and among Elanco Animal Health Incorporated, solely in its role as performance guarantor, Elanco SPEAR LLC, as borrower, Elanco US Inc., as servicer, Coöperatieve Rabobank U.A., New York Branch, as Administrative Agent, and the lenders from time to time party thereto. Exhibit 10.1 EXECUTION COPY FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT This FIRST AMENDMENT TO RECEIVABLES LOAN AGREEMENT, dated as of June 25, 2025 (this “Amendment”), is entered into by and among Elanco Spear LLC, a Delaware limited liability company, as borrower (the “Borrower”), Elanco US Inc. (“Elanco”), a Delaware corporation, as servicer (the “Servicer”), the various lenders and lender a
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2500 Innovation Way Greenfield, Indiana (Address of principal e
May 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2025 Elanco Animal Healt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 21, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
May 28, 2025	EX-10.2	Transition Agreement, dated as of May 21, 2025, between Elanco Animal Health Incorporated and Todd Young. Exhibit 10.2 May 21, 2025 Todd Young Re:          Transition Agreement Dear Todd, The purpose of this letter (“Transition Agreement”) is to confirm the terms of your transition and separation from employment with Elanco Animal Health Incorporated (the “Company”). Transition Period Your last day of employment with the Company will be August 31, 2025 (your “Separation Date”). Between now and the clo
May 28, 2025	EX-99.1	Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Colleen Dekker (317) 989-7011 [email protected] Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer GREENFIELD, Ind. (May 28, 2025) Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive
May 28, 2025	EX-10.1	Employment Offer Letter, dated as of May 20, 2025, between Elanco Animal Health Incorporated and Robert VanHimbergen. Exhibit 10.1 05/20/2025 Robert VanHimbergen 8124 W. Knightsbridge Drive Mequon, Wisconsin 53097 Dear Bob, It is my pleasure to extend to you a formal offer of employment with Elanco US Inc. and to outline the provisions of that offer in detail. The position is Executive Vice President & Chief Financial Officer reporting to Jeff Simmons, President & Chief Executive Officer. This offer includes an o
May 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2025 Elanco Animal Healt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
May 7, 2025	EX-10.1	The Elanco Corporate Bonus Plan (as amended effective January 1, 2025) TABLE OF CONTENTS The Elanco Corporate Bonus Plan (as amended effective January 1, 2025) TABLE OF CONTENTS SECTION 1.
May 7, 2025	EX-10.5	Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).
May 7, 2025	EX-10.2	Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement 4907-1064-5017.1 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at
May 7, 2025	EX-10.4	Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”).
May 7, 2025	EX-99.1	Elanco Animal Health Reports First Quarter 2025 Results Accelerating Debt Paydown in 2025 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2025 Results Accelerating Debt Paydown in 2025 •First Quarter 2025 Financial Results: ◦Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic const
May 7, 2025	EX-10.3	Elanco Animal Health Incorporated Performance-Based Award Agreement Elanco Animal Health Incorporated Performance-Based Award Agreement This Performance-Based Award is granted on , 2025 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”).
May 7, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (I.R
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health
March 27, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the ap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat
March 27, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the ap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat
March 17, 2025	EX-99.1	Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Colleen Dekker (317) 989-7011 [email protected]   Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets GREENFIELD, Ind. (March 17, 2025) Elanco Animal Health Incor
March 17, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
February 25, 2025	EX-10.23	ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.23 ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://o
February 25, 2025	EX-19	ELANCO ANIMAL HEALTH INCORPORATED INSIDER TRADING AND REGULATION FD POLICY Exhibit 19 ELANCO ANIMAL HEALTH INCORPORATED INSIDER TRADING AND REGULATION FD POLICY Introduction The purpose of this Insider Trading and Regulation FD Policy (this “Policy”) is to help Elanco Animal Health Incorporated and its subsidiaries (the “Company”) comply with U.
February 25, 2025	EX-99.1	Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results •Fourth Quarter 2024 Financial Results: ◦Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic co
February 25, 2025	EX-4.5	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.5 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Elanco Animal Health Incorporated (“Elanco”) has one class of securities, its common stock, no par value, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of common stock The following is a summary of Elanco
February 25, 2025	EX-21.1	SUBSIDIARIES OF THE COMPANY SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2024, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Dista Products Limited United Kingdom EIO Insurance Company, Inc. Tennessee (United States) Elanco (Shanghai) Animal Health Co., Ltd. China
February 25, 2025	EX-10.16	The Elanco Corporate Bonus Plan (as amended effective January 1, 2024) SECTION 1. PURPOSE Exhibit 10.16 The Elanco Corporate Bonus Plan (as amended effective January 1, 2024) SECTION 1. PURPOSE The purpose of The Elanco Corporate Bonus Plan (the “Plan”) is to encourage and promote eligible employees to create and deliver innovative animal health-based solutions that enable Elanco Animal Health Incorporated (the “Company” or “Elanco”) to meet or exceed its business objectives through a
February 25, 2025	EX-10.24	ELANCO ANIMAL HEALTH INCORPORATED PERFORMANCE-BASED AWARD AGREEMENT Exhibit 10.24 ELANCO ANIMAL HEALTH INCORPORATED PERFORMANCE-BASED AWARD AGREEMENT This Performance-Based Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://onlineservice
February 25, 2025	EX-10.22	ELANCO ANIMAL HEALTH INCORPORATED NONQUALIFIED STOCK OPTION AWARD AGREEMENT Exhibit 10.22 ELANCO ANIMAL HEALTH INCORPORATED NONQUALIFIED STOCK OPTION AWARD AGREEMENT This Nonqualified Stock Option is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at htt
February 25, 2025	EX-10.12	ELANCO ANIMAL HEALTH INCORPORATED EXECUTIVE DEFERRAL AND STOCK MATCH PLAN Exhibit 10.12 ELANCO ANIMAL HEALTH INCORPORATED EXECUTIVE DEFERRAL AND STOCK MATCH PLAN Elanco Animal Health Incorporated (the "Company"), hereby amends and restates the Elanco Animal Health Incorporated Executive Deferral Plan, changes the plan name to Elanco Animal Health Incorporated Executive Deferral and Stock Match Plan (the "Plan") and becomes a sub-plan of the Elanco Stock Plan, effective
February 25, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission Fil
February 25, 2025	EX-10.13	ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.13 ELANCO ANIMAL HEALTH INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award is granted on , 2024 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at https://o
February 25, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ
February 25, 2025	EX-10.25	ELANCO ANIMAL HEALTH INCORPORATED 2018 ELANCO STOCK PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS Exhibit 10.25 ELANCO ANIMAL HEALTH INCORPORATED 2018 ELANCO STOCK PLAN OMNIBUS AMENDMENT TO STOCK OPTION AGREEMENTS This Omnibus Amendment, dated as of March 29, 2024, amends the terms and conditions of those certain award agreements governing the terms of stock option awards granted under the 2018 Elanco Stock Plan (the “Plan”), by and between Elanco Animal Health Incorporated (the “Company”) and
January 13, 2025	EX-99.1	© 2025 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation Exhibit 99.1 J.P. Morgan Healthcare Conference January 14, 2025 Jeff Simmons President & Chief Executive Officer © 2025 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, our expected 2024 full year and fou
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 Elanco Animal H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
November 12, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 11, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
November 12, 2024	EX-99.1	Elanco Strengthens Board of Directors with Addition of Stacey Ma Ma brings deep manufacturing and innovation expertise Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Elanco Strengthens Board of Directors with Addition of Stacey Ma Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind. (Nove
November 7, 2024	EX-99.1	Elanco Animal Health Reports Third Quarter 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2024 Results •Third Quarter 2024 Financial Results ◦Revenue of $1,030 million, organic constant currency growth of 1% ◦Reported Net Income of $364 million, Adju
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Hea
October 16, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 16, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
August 13, 2024	EX-10.1	Incremental Assumption Agreement dated August 13, 2024 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent. Exhibit 10.1 EXECUTION VERSION INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this “Agreement”) dated and effective as of August 13, 2024 (the “Effective Date”), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the “Company”), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the “Borrowers” and each, individually, a “Borro
August 13, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 13, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I
August 8, 2024	EX-2.1	FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT Exhibit 2.1 EXECUTION VERSION FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT This FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), is hereby entered into as of July 1, 2024, by and between Elanco Animal Health, Inc., an Indiana corporation (“Seller” and, together with the Seller Divesting Entities, the “Seller Parties”), and Intervet International B.V., a Dutch private company with lim
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Elanco Animal Heal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (
August 8, 2024	EX-99.1	Elanco Animal Health Reports Second Quarter 2024 Results Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2024 Results Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture •Second Quarter 2024 Financial Results ◦Revenue of $1,1
July 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Elanco Animal Healt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
July 9, 2024	EX-99.1	Elanco Completes Sale of Aqua Business Transaction concentrates Elanco’s focus on significant value creation opportunities and accelerates deleveraging progress Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Katy Grissom (317) 273-9248 [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 [email protected] Elanco Completes Sale of Aqua Business Transaction concentrates Elanco’s focus on significant value creation opportunities and accelerates deleveragin
July 3, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 3, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
July 3, 2024	EX-10.1	Amendment No. 2, dated as of July 3, 2024, to the Credit Agreement, dated as of August 1, 2020, by and among Elanco Animal Health Incorporated, as borrower, Elanco US Inc., as co-borrower, the subsidiary loan parties party thereto, the lenders and issuing banks party thereto from time to time, Goldman Sachs Bank USA, as term facility agent, collateral agent and security trustee, and JPMorgan Chase Bank, N.A., as revolving facility agent. Exhibit 10.1 AMENDMENT NO. 2 TO CREDIT AGREEMENT THIS AMENDMENT NO. 2 TO CREDIT AGREEMENT (this “Agreement”), dated as of July 3, 2024, is entered into among ELANCO ANIMAL HEALTH INCORPORATED, a corporation formed under the laws of Indiana (the “Borrower”), ELANCO US INC., a corporation formed under the laws of Delaware (the “Co-Borrower”, and together with the Borrower, the “Borrowers”), the SUBS
June 4, 2024	EX-3.1	Elanco Animal Health Incorporated Amended and Restated Articles of Incorporation, effective May 30, 2024. Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED (an Indiana corporation) AMENDED AND RESTATED ARTICLES OF INCORPORATION (As amended and restated May 30, 2024) 1. The name of the Corporation shall be ELANCO ANIMAL HEALTH INCORPORATED. 2. The purposes for which the Corporation is formed are to engage in any lawful act or activity for which a corporation may be organized under the Indiana Business Corp
June 4, 2024	EX-3.2	Elanco Animal Health Incorporated Amended and Restated Bylaws, effective May 30, 2024. Exhibit 3.2 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of May 30, 2024 (Effective May 30, 2024) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page ARTICLE I The Shareholders 1 SECTION 1.1. Annual Meetings 1 SECTION 1.2. Special Meetings 1 SECTION 1.3. Time, Place, and Conduct of Meetings 4 SECTION 1.4. Notice of Meetings 4 SECTION 1.5. Quorum 4 S
June 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Elanco Animal Healt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
May 28, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Shiv O’Neill
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File (I.R
May 8, 2024	EX-99.1	Elanco Animal Health Reports First Quarter 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2024 Results •First Quarter 2024 Financial Results ◦Revenue of $1,205 million ◦Reported Net income of $32 million, Adjusted Net income of $167 million ◦Adjusted
April 19, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat
April 19, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy St
April 8, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat
April 1, 2024	EX-99.1	Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors New Directors Join the Board’s Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Joele Frank: Kelly Sullivan / Adam Pollack (212) 355-4449 Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Walla
April 1, 2024	EX-10.1	Cooperation Agreement, dated as of March 29, 2024, by and among Elanco Animal Health Incorporated, Ancora Catalyst Institutional, LP and the other person and entities listed thereto. Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of March 29, 2024, is made by and among Elanco Animal Health Incorporated, an Indiana corporation (the “Corporation”), and the entities and natural persons set forth under the “Ancora Parties” caption in the signature pages hereto and their Affiliates or Associates (as such terms are defined below) (collecti
April 1, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 29, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
February 29, 2024	EX-1	EX-1 Exhibit 1
February 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
February 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
February 29, 2024	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
February 26, 2024	EX-18	February 26, 2024 Exhibit 18 February 26, 2024 Board of Directors Elanco Animal Health, Inc. 2500 Innovation Way Greenfield, IN 46140 Ladies and Gentlemen: Note 2 of the Notes to the consolidated financial statements of Elanco Animal Health, Inc., included in its Annual Report on Form 10-K for the year ended December 31, 2023, describes a change in the method of accounting for inventory valuation from the weighted
February 26, 2024	EX-97	ELANCO ANIMAL HEALTH INCORPORATED REQUIRED COMPENSATION RECOVERY POLICY Adopted August 15, 2023 Exhibit 97 ELANCO ANIMAL HEALTH INCORPORATED REQUIRED COMPENSATION RECOVERY POLICY Adopted August 15, 2023 Policy The Board of Directors (the “Board”) of ELANCO ANIMAL HEALTH INCORPORATED (the “Company”) has adopted this Required Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission (“SEC”) regulations promulgated thereunder, and applicable New York Stock Exchange (“NYSE”) listing standards.
February 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Elanco Animal H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission Fil
February 26, 2024	EX-21.1	SUBSIDIARIES OF THE COMPANY SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2023, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Dista Products Limited United Kingdom EIO Insurance Company, Inc. Tennessee (United States) Elanco (Shanghai) Animal Health Co., Ltd. China
February 26, 2024	EX-99.1	Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results •Fourth Quarter 2023 Financial Results: ◦Revenue of $1,035 million ◦Reported Net Loss of $141 million, Adjusted Net Income of $39 mi
February 26, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ
February 13, 2024	SC 13G/A	ELAN / Elanco Animal Health Incorporated / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d759338dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3 )* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat
February 13, 2024	SC 13G/A	ELAN / Elanco Animal Health Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0821-elancoanimalhealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Elanco Animal Health Inc Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t
February 12, 2024	SC 13G/A	ELAN / Elanco Animal Health Incorporated / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 elana621224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo
February 5, 2024	EX-2.1	Asset Purchase Agreement by and between Elanco Animal Health Incorporated as Seller and Intervet International as Buyer dated as of February 5, 2024.*   Exhibit 2.1   EXECUTION VERSION     ASSET PURCHASE AGREEMENT   BY AND BETWEEN   ELANCO ANIMAL HEALTH, INC.,   as Seller   and   INTERVET INTERNATIONAL B.V.,   as Buyer   DATED AS OF FEBRUARY 5, 2024           Table of Contents     Page     Article I Definitions 1 Section 1.01 Certain Defined Terms 1       Article II Purchase and Sale; Closing 1 Section 2.01 Purchase and Sale of Transferred Asset
February 5, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
February 5, 2024	EX-99.1	Elanco Announces Sale of Aqua Business for $1.3 Billion Transaction reinforces Elanco’s commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1. Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Announces Sale of Aqua Business for $1.3 Billion Transaction reinforces Elanco’s commitment to most significant value creation opportunities in pet health a
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Elanco Animal He UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 8, 2024	EX-99.1	© 2024 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation Exhibit 99.1 J.P. Morgan Healthcare Conference January 9, 2024 Jeff Simmons President & Chief Executive Officer © 2024 Elanco or its affiliates This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation, our long-term revenue and earnings g
January 2, 2024	EX-99.1	Elanco Animal Health Announces Planned Board Leadership Changes and Corporate Governance Actions Lawrence Kurzius to become next Chairman of the Board Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Animal Health Announces Planned Board Leadership Changes and Corporate Governance Actions Lawrence Kurzius to become next Chairman of
January 2, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
November 8, 2023	SC 13G/A	ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 elana5110823.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo
November 7, 2023	EX-99.1	Elanco Animal Health Reports Third Quarter 2023 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2023 Results •Third Quarter 2023 Financial Results ◦Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange ra
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Hea
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 001-38661 82-5497352 (State or other jurisdiction of (Commission File
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Elanco Animal He UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
October 4, 2023	EX-99.1	Elanco Announces Corporate Governance Enhancements Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker, +1.317.989.7011, [email protected] Investor Contact: Kathryn Grissom, +1.317.273.9284, [email protected] Elanco Announces Corporate Governance Enhancements GREENFIELD, Ind. (October 4, 2023) – Elanco Animal Health Incorporated (NYSE: ELAN) announ
September 11, 2023	SC 13G/A	ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health I
August 7, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
August 7, 2023	EX-10.1	Receivables Loan Agreement among Elanco SPEAR LLC, Elanco US Inc., The Various Lenders and Lender Agents from Time to Time Party Thereto and Coöperatieve Rabobank U.A., New York Branch, dated as of August 3, 2023 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on August 7, 2023). Exhibit 10.1 EXECUTION COPY RECEIVABLES LOAN AGREEMENT among ELANCO SPEAR LLC, as Borrower ELANCO US INC., as initial Servicer THE VARIOUS LENDERS AND LENDER AGENTS FROM TIME TO TIME PARTY HERETO and COÖPERATIEVE RABOBANK U.A., NEW YORK BRANCH, as Administrative Agent Dated as of August 3, 2023 Table of Contents Page ARTICLE I AMOUNTS AND TERMS OF THE ADVANCES 1 Section 1.1. Advances and Making Lo
August 7, 2023	EX-99.1	Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance · Second Quarter 2023 Financial Results ◦ Revenue of $1,057 million, impacted by an estimated $90-$110 million of re
July 13, 2023	EX-99.2	Exhibit 99.2 Seresto® Stewardship Program On July 13, 2023, Elanco Animal Health Incorporated and the Environmental Protection Agency (EPA) announced that the EPA, with support from the Food and Drug Administration (FDA), completed its comprehensive, Exhibit 99.2 Seresto® Stewardship Program On July 13, 2023, Elanco Animal Health Incorporated and the Environmental Protection Agency (EPA) announced that the EPA, with support from the Food and Drug Administration (FDA), completed its comprehensive, multi-year review of the Seresto® flea and tick collar. EPA confirms continued registration of the collar. Comprehensive data affirms the safety prof
July 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Elanco Animal Heal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co
July 13, 2023	EX-99.1	Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact: Season Solorio (765) 316-0233 [email protected] Investor Contact: Kathryn Grissom (317) 273-9284 [email protected] Environmental Protection Agency (EPA) Completes Review of Seresto® Collar and Confirms Continued Registration; Data Affirms Safety Profile of the Product · Comprehensive, multi-year review by the EPA, with support
July 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Elanco Animal Healt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
May 25, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Marcela A. Ki
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 Elanco Animal Health UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm
May 19, 2023	S-8	As filed with the Securities and Exchange Commission on May 19, 2023 As filed with the Securities and Exchange Commission on May 19, 2023 Registration Statement No.
May 19, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Elanco Animal Health Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, no par value 457(c) and 457(h) 5,375,000 (2) $ 8.
May 9, 2023	EX-99.1	Elanco Animal Health Reports First Quarter 2023 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2023 Results · First Quarter 2023 Financial Results ◦ Revenue of $1,257 million, including an estimated $90-$110 million benefit from customer purchasing shifte
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Elanco Animal Health UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health
April 6, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D
April 6, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat
March 1, 2023	EX-4.5	Exhibit 4.5 EXHIBIT 4.5 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Elanco Animal Health Incorporated (“Elanco”) has one class of securities, its common stock, no par value, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of common stock The following is a summary of Elanco
March 1, 2023	EX-21.1	SUBSIDIARIES OF THE COMPANY SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2022, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Aratana Therapeutics, Inc. Delaware (United States) ChemGen Corporation Massachusetts (United States) Dista Products Limited United Kingdom
March 1, 2023	EX-10.26	Elanco Animal Health Incorporated Performance-Based Award Agreement EXHIBIT 10.26 Elanco Animal Health Incorporated Performance-Based Award Agreement This Performance-Based Award is granted on , 2022 (“Grant Date”), by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Performance-Based Award Agreement (the “Grantee”). Number of Shares: Log into UBS account at http://equity.elanco
March 1, 2023	EX-99.1	Elanco Animal Health Incorporated Consolidated Statements of Operations (Dollars and shares in millions, except per share data) Exhibit 99.1 The financial tables in this Exhibit 99.1 reflect the revisions to previously reported financial results related to the identified immaterial errors as noted in the Form 8-K/A filed March 1, 2023 (the "Form 8-K/A"). Revised Financial Highlights The table below includes the following pet health revenue revisions: fourth quarter of 2022 was decreased by $3 million and fourth quarter of
March 1, 2023	EX-10.23	The Elanco Corporate Bonus Plan (as amended effective January 1, 2023) TABLE OF CONTENTS EXHIBIT 10.23 The Elanco Corporate Bonus Plan (as amended effective January 1, 2023) TABLE OF CONTENTS SECTION 1. PURPOSE 1 SECTION 2. DEFINITIONS 1 SECTION 3. ADMINISTRATION 6 SECTION 4. PARTICIPATION IN THE PLAN 7 SECTION 5. DEFINITION AND COMPUTATION OF COMPANY BONUS 8 SECTION 6. TIME OF PAYMENT 11 SECTION 7. ADMINISTRATIVE GUIDELINES 12 SECTION 8. MISCELLANEOUS 12 SECTION 9. AMENDMENT, SUSPENS
March 1, 2023	EX-10.27	EXHIBIT 10.27 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on _______ __, 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation, (“Elanco” or the “Com ex1027elanconon-qualifie EXHIBIT 10.27 Elanco Animal Health Incorporated Nonqualified Stock Option Award Agreement This Nonqualified Stock Option is granted on , 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation, (“Elanco” or the “Company”), to the Eligible Individual who has received this Nonqualified Stock Option Award Agreement (the “Grantee”). Number of Shares: L
March 1, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-38661 Elan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employ
March 1, 2023	EX-10.25	EXHIBIT 10.25 Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on __________ __, 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Com ex1025elanco-onxcyclersu EXHIBIT 10.25 Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2022 (“Grant Date”) by Elanco Animal Health Incorporated, an Indiana corporation (“Elanco” or the “Company”), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the “Grantee”). Number of Shares: Log into
March 1, 2023	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation
February 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal H UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
February 21, 2023	EX-99.1	Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results • Fourth Quarter 2022 Financial Results: ◦ Revenue of $988 million ◦ Reported Net Loss of $54 million, Adjusted Net Income of $95 mi
February 14, 2023	SC 13G/A	ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d465178dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate
February 9, 2023	SC 13G/A	ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 9, 2023	SC 13G/A	ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 elana420923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate bo
February 1, 2023	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on February 13, 2023, pursuant to the provisions of Rule 12d2-2 (a).
January 31, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 9, 2023	EX-99.1	© 2023 Elanco or its affiliates This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitat EX-99.1 2 tm232554d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 J.P. Morgan Healthcare Conference January 10, 2023 Jeff Simmons President & Chief Executive Officer © 2023 Elanco or its affiliates This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
December 22, 2022	SC 13D/A	ELAN / Elanco Animal Health Inc / Sachem Head Capital Management LP - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 28
December 22, 2022	EX-99.7	TRADING DATA EX-99.7 2 sa58394498-ex997.htm TRADING DATA EXHIBIT 99.7 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Sachem Head Funds. Name Trade Date Buy/ Sell No. of Shares/ Quantity Unit Cost/ Proceeds Security Sachem Head LP 11/01/2022 Buy 6,600 13.19 Common Stock* Sachem Head LP 12/01/2022 Sell 7,700 12.87 Common Stock
December 9, 2022	SC 13G/A	ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
November 10, 2022	SC 13G/A	ELAN / Elanco Animal Health Inc / Aristotle Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 28414H103 (CUSIP Number) Michelle Gosom Arist
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to COMMISSION FILE NUMBER 001-38661 Elanco Animal Health In
November 8, 2022	EX-99.1	Elanco Animal Health Reports Third Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2022 Results ? Third Quarter 2022 Financial Results ? Revenue of $1,028 million ? Reported Net Loss of $49 million, Adjusted Net Income of $96 million ? Adjuste
September 9, 2022	EX-99.6	Scott D. Ferguson 250 West 55th Street, 34th Floor New York, NY 10019 EXHIBIT 99.6 Scott D. Ferguson 250 West 55th Street, 34th Floor New York, NY 10019 September 7, 2022 Board of Directors Elanco Animal Health Incorporated 2500 Innovation Way Greenfield, IN 46140 Attention: Chairman of the Board of Directors Re: Resignation Ladies and Gentlemen: I hereby resign from my position as a director of Elanco Animal Health Incorporated (the ?Company?) and from any and all
September 9, 2022	SC 13D/A	ELAN / Elanco Animal Health Inc / Sachem Head Capital Management LP - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 28
September 9, 2022	EX-99.5	TRADING DATA EXHIBIT 99.5 TRADING DATA The following table sets forth all transactions in the Common Stock of the Issuer effected in the last sixty days by the Sachem Head Funds. Name Trade Date Buy/ Sell No. of Shares/ Quantity Unit Cost/ Proceeds Security SH Stony Creek Master Ltd. 9/8/22 Buy 800,000 $14.4649 Common Stock
September 8, 2022	EX-99.1	Elanco Announces Changes to its Board of Directors Scott Ferguson steps down from the Board Sachem Head expresses confidence in Elanco’s leadership and strategy Exhibit 99.1 Elanco Announces Changes to its Board of Directors Scott Ferguson steps down from the Board Sachem Head expresses confidence in Elanco?s leadership and strategy GREENFIELD, Ind. ? September 8, 2022 ? Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Scott Ferguson, founder and managing partner of Sachem Head Capital Management LP (?Sachem Head?), has stepped down fro
September 8, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
August 8, 2022	EX-10.1	Consulting Agreement, dated April 12, 2022, by and between Aaron Schacht and Elanco US Inc. (filed herewith). Exhibit 10.1 Consulting Agreement This CONSULTING AGREEMENT (the ?Agreement?) is made by and between Aaron Schacht (?you? or ?Consultant?) and Elanco US Inc., and its affiliates (the ?Company?) (collectively, the ?Parties?). RECITALS WHEREAS, the Company desires that Consultant provide certain Services (as defined below) to the Company and its affiliates; and WHEREAS, Consultant desires to perform
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co
August 8, 2022	EX-3.1	Amended and Restated Articles of Incorporation of Elanco Animal Health Incorporated, effective May 18, 2022 ( Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED (an Indiana corporation) AMENDED AND RESTATED ARTICLES OF INCORPORATION (As amended and restated May 20, 2022) 1. The name of the Corporation shall be ELANCO ANIMAL HEALTH INCORPORATED. 2. The purposes for which the Corporation is formed are to engage in any lawful act or activity for which a corporation may be organized under the Indiana Business Corp
August 8, 2022	EX-99.1	Elanco Animal Health Reports Second Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2022 Results ? Second Quarter 2022 Financial Results ? Revenue of $1,177 million ? Reported Net Loss of $22 million, Adjusted Net Income of $177 million ? Adju
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ Transition Report Pursuant To Section UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as
July 8, 2022	SC 13G	ELAN / Elanco Animal Health Inc / DODGE & COX - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
June 29, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
June 29, 2022	EX-10.1	Incremental Assumption Agreement dated June 28, 2022 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Bank of America, N.A., as incremental term lender, each other person party thereto as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent. ? Exhibit 10.1 ? Execution Version ? INCREMENTAL ASSUMPTION AGREEMENT ? THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of June?28, 2022 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a
May 26, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or other jurisdiction of incorporation) 001-38661 (Commission file number) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 46140 (Zip code) Marcela A. Ki
May 19, 2022	S-8	As filed with the Securities and Exchange Commission on May 19, 2022 As filed with the Securities and Exchange Commission on May 19, 2022 Registration Statement No.
May 19, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Elanco Animal Health Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, no par value 457(c) and 457(h) 625,000 (1) $ 22.
May 19, 2022	EX-3.1	Amended and Restated Bylaws of Elanco Animal Health Incorporated, effective May 18, 2022 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the Commission on May 19, 2022). Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of February 22, 2022 (Effective May 18, 2022) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page Article I The Shareholders 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Time, Place, and Conduct of Meetings 1 Section 1.4. Notice of Meetings 1 Section 1.5. Quoru
May 19, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm
May 19, 2022	EX-10.1	Elanco Animal Health Incorporated Amended and Restated Employee Stock Purchase Plan. Exhibit 10.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN The purpose of the Elanco Animal Health Incorporated Employee Stock Purchase Plan, as it may be amended from time to time (the ?Plan?), is to assist employees of Elanco Animal Health Incorporated, an Indiana corporation, and any successor corpora
May 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi
May 9, 2022	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ Transition Report Pursuant To Section 13 or 15(d) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in
May 9, 2022	EX-99.1	Elanco Animal Health Reports First Quarter 2022 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2022 Results ? First Quarter 2022 Financial Results ? Revenue of $1,225 million ? Reported Net Income of $48 million, Adjusted Net Income of $177 million ? Adju
April 20, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 19, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
April 20, 2022	EX-10.1	Incremental Assumption Agreement dated April 19, 2022 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender, and Goldman Sachs Bank USA, as the term facility agent. Exhibit 10.1 EXECUTION VERSION INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of April 19, 2022 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a ?Borrow
April 13, 2022	EX-99.1	Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein product Exhibit 99.1 Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology BiomEdit intends to discover and develop animal health products that leverage microbiome science to improve animal health, animal protein production, and livestock disease monitoring GREENFIELD, IN and BOSTON, MA (April 11, 2022) ? Elanco Animal Health Incorporated (NYSE: ELAN), a
April 13, 2022	EX-99.2	Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes Exhibit 99.2 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Incorporated Announces Early Results of Tender Offer and Increase in Tender Cap for 2023 Notes Greenfield, IN, (April 12, 2022) (BUSINESSWIRE) - Elanco Animal Health Incorporated (NY
April 13, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
April 6, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 6, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 ny20002367x3def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On
March 29, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
March 29, 2022	EX-99.1	Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Incorporated Announces Tender Offer for 2023 Notes Greenfield, IN, (March 29, 2022) (BUSINESSWIRE) - Elanco Animal Health Incorporated (NYSE: ELAN) (?Elanco?) today announced the com
March 24, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
February 28, 2022	EX-10.17	Services Agreement, dated as of January 1, 2022, by and between MBRD Service Company and Elanco US Inc. (incorporated by reference to Exhibit 10.17 of the Annual Report on Form 10-K filed with the SEC on February 28, 2022). Exhibit 10.17 SERVICES AGREEMENT This Services Agreement (this ?Agreement?), dated as of January 1, 2022 (the ?Effective Date?), is by and between MBRD Service Company, an Indiana limited liability company, with offices located at 9400 Priority Way W. Drive, Indianapolis, IN 46240 (the ?Service Provider?) and Elanco US Inc., a Delaware corporation, with offices located at 2500 Innovation Way, Gree
February 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number 001-38661 Elanco Anima UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incor
February 28, 2022	EX-21.1	SUBSIDIARIES OF THE COMPANY SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2021, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Aratana Therapeutics, Inc. United States ChemGen Corporation Massachusetts Dista Products Limited United Kingdom Elanco (Shanghai) Animal He
February 24, 2022	EX-3.1	Elanco Animal Health Incorporated Amended and Restated Bylaws, effective February 22, 2022. Exhibit 3.1 ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS Adopted as of February 22, 2022 (Effective February 22, 2022) ELANCO ANIMAL HEALTH INCORPORATED AMENDED AND RESTATED BYLAWS INDEX Page Article I The Shareholders 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Time, Place, and Conduct of Meetings 1 Section 1.4. Notice of Meetings 1 Section 1.5.
February 24, 2022	EX-99.1	Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Kathryn Grissom (317) 273-9284 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2021 Results ? Full year 2021 revenue was $4,765 million, an increase of 46 percent, including $1,311 million of incremental revenue from Bayer A
February 24, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
February 14, 2022	SC 13G/A	ELAN / Elanco Animal Health Inc / Aristotle Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 28414H103 (CUSIP Number) Michelle Gosom Arist
February 10, 2022	SC 13G/A	ELAN / Elanco Animal Health Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Elanco Animal Health Inc (Name of Issuer) COM (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
February 9, 2022	SC 13G/A	ELAN / Elanco Animal Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
January 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 10, 2022	EX-99.1	January 11, 2022 J.P. Morgan Healthcare Conference Jeff Simmons President & Chief Executive Officer Exhibit 99.1 January 11, 2022 J.P. Morgan Healthcare Conference Jeff Simmons President & Chief Executive Officer This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 (Exchange Act), including, without limitation , our long - term revenue and earnings growth expectations, reduc
January 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 1, 2022 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction (Commission (I.R.S.
November 30, 2021	EX-99.1	Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Dave Pugh (317) 361-9892 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Announces Changes to Simplify Organizational Structure, Drive Profitable Growth and Focus Investments on Growth and Innovation Opportunities ? Streamlining and simplifying organizational structure to reduce
November 30, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 29, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
November 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
November 5, 2021	EX-99.1	Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Dave Pugh (317) 361-9892 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Third Quarter 2021 Results Exceeding Revenue Guidance; Raising Full Year 2021 Revenue Guidance ? Third quarter revenue increased 27 percent, benefiting from increased scale and diversif
November 5, 2021	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ Transition Report Pursuant To Section 13 or 15 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specifie
October 5, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 5, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
October 5, 2021	EX-99.1	1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Announces New Innovation Leader, Additional Strategic Move to Increase Focus on High-Value, Late-Stage Pet Health Pipeline Progress ? Ellen de Brabander, Ph.D., joins Elanco to lead Innovation and R
August 30, 2021	SC 13D/A	KIN / Kindred Biosciences Inc / Elanco Animal Health Inc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Kindred Biosciences, Inc. (Name of Subject Company — Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 494577109 (CUSIP Number of Class of Securities) Marcela A. Kirberger General Counsel and Corporate Secretary Elanco Ani
August 30, 2021	EX-99.1	Elanco Closes Acquisition of Kindred Biosciences Differentiated, Disruptive Portfolio Positions Elanco for Next Era of Pet Health Growth Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga, 302-897-0668, [email protected] Media Contact: Colleen Parr Dekker, 317-989-7011, [email protected] Elanco Closes Acquisition of Kindred Biosciences Differentiated, Disruptive Portfolio Positions Elanco for Next Era of Pet Health Growth GREENFIELD,
August 30, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 27, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
August 12, 2021	EX-10.1	Incremental Assumption Agreement dated August 12, 2021 by and among Elanco Animal Health Incorporated, Elanco US Inc., the subsidiary loan parties party thereto, Farm Credit Mid-America, PCA, as incremental term lender and Goldman Sachs Bank USA, as the term facility agent Exhibit 10.1 Execution Version INCREMENTAL ASSUMPTION AGREEMENT THIS INCREMENTAL ASSUMPTION AGREEMENT (this ?Agreement?) dated and effective as of August 12, 2021 (the ?Effective Date?), is among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the ?Company?), ELANCO US INC., a Delaware corporation (together with the Company, collectively, the ?Borrowers? and each, individually, a ?Borro
August 12, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (C
August 10, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 9, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 9, 2021	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ☐ Transition Report Pursuant To Section 13 or 15(d) o SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in
August 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Co
August 9, 2021	EX-99.1	Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook ? Revenue in the second quarter was $1,279 million, comprised of $7
August 9, 2021	S-8	As filed with the Securities and Exchange Commission on August 9, 2021 As filed with the Securities and Exchange Commission on August 9, 2021 Registration Statement No.
August 9, 2021	EX-99.1	Press Release issued by Elanco Animal Health Incorporated, August 9, 2021. Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Second Quarter 2021 Results Exceeded second quarter 2021 guidance; Increasing full year 2021 revenue outlook ? Revenue in the second quarter was $1,279 million, comprised of $7
August 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
August 2, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
July 1, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
July 1, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Healt DFAN14A 1 tm2118507d8dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or
July 1, 2021	EX-2.1	Exhibit 2.1 to Elanco’s Current Report on Form 8-K filed with the SEC on July 1, 2021 Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This First Amendment (this ?Amendment?) is made and entered into as of June 30, 2021, by and among Elanco Animal Health Incorporated, an Indiana corporation (?Parent?), Knight Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Parent (?Merger Sub?), and Kindred Biosciences, Inc., a Delaware corporation (the ?Co
July 1, 2021	EX-2.1	First Amendment to Agreement and Plan of Merger, dated as of June 30, 2021, by and among Elanco Animal Health Incorporated, Knight Merger Sub, Inc. and Kindred Biosciences, Inc. Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This First Amendment (this ?Amendment?) is made and entered into as of June 30, 2021, by and among Elanco Animal Health Incorporated, an Indiana corporation (?Parent?), Knight Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Parent (?Merger Sub?), and Kindred Biosciences, Inc., a Delaware corporation (the ?Co
June 25, 2021	EX-99.5	Joint Filing Agreement, dated as of June 25, 2021, between Elanco Animal Health Incorporated and Knight Merger Sub, Inc. Exhibit 99.5 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of Kindred Biosciences, Inc., a Delaware corporation, and further agree
June 25, 2021	EX-99.3	Exclusivity Agreement, dated as of May 31, 2021, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc. Exhibit 99.3 STRICTLY PRIVATE & CONFIDENTIAL May 31, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite #200 Burlingame, CA 94010 Dear Dr. Chin, Reference is made to our discussions regarding the proposed acquisition (the ?Proposed Transaction?) of all of the issued and outstanding equity interests of Kindred Biosciences, Inc. (the ?Company?) by
June 25, 2021	EX-99.4	Amendment to Exclusivity Agreement, dated as of June 11, 2021, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc. Exhibit 99.4 STRICTLY PRIVATE & CONFIDENTIAL June 11, 2021 Richard Chin, M.D. Chief Executive Officer Kindred Biosciences, Inc. 1555 Bayshore Highway, Suite #200 Burlingame, CA 94010 Dear Dr. Chin, Reference is made to that letter agreement (the ?Letter Agreement?), dated as of May 31, 2021, between Kindred Biosciences, Inc. (the ?Company?) and Elanco Animal Health Incorporated (?Elanco?). In acco
June 25, 2021	EX-99.2	Mutual Confidentiality Agreement, dated as of January 11, 2020, between Elanco Animal Health Incorporated and Kindred Biosciences, Inc. Exhibit 99.2 MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this ?Agreement?) is entered into as of January 11, 2020 by and between Kindred Biosciences, Inc., a Delaware corporation with its principal place of business at 1555 Bayshore Highway, Suite 200, Burlingame, California 94010 USA (?KindredBio?) and Elanco US Inc., a Delaware corporation with its principal place of
June 25, 2021	SC 13D	KIN / Kindred Biosciences Inc / Elanco Animal Health Inc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 Kindred Biosciences, Inc. (Name of Subject Company — Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 494577109 (CUSIP Number of Class of Securities) Marcela A. Kirberger General Counsel and Corporate Secretary Elanco Animal Health Incorpora
June 17, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant x Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
June 16, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Com
June 16, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DFAN14A 1 tm2118507d5dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by R
June 16, 2021	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2021 Elanco Animal Healt DFAN14A 1 tm2118507d4dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or
June 16, 2021	EX-99.3	FORM OF SUPPORT AGREEMENT Exhibit 99.3 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this ?Agreement?), dated June 15, 2021, is by and among [ ] (?Stockholder?), Elanco Animal Health Incorporated, an Indiana corporation (?Parent?), and Knight Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (?Merger Sub?). WHEREAS, simultaneously with the delivery and execution of this Agreement,
June 16, 2021	EX-2.1	Agreement and Plan of Merger, dated as of June 15, 2021, among Elanco Animal Health Incorporated, Knight Merger Sub, Inc. and Kindred Biosciences, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Elanco Animal Health Incorporated with the SEC on June 16, 2021). Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ELANCO ANIMAL HEALTH INCORPORATED, KNIGHT MERGER SUB, INC. and KINDRED BIOSCIENCES, INC. dated as of June 15, 2021 TABLE OF CONTENTS Page AGREEMENT AND PLAN OF MERGER 1 Article I THE MERGER 2 Section 1.1. The Merger 2 Section 1.2. Closing 2 Section 1.3. Effective Time 2 Article II SURVIVING CORPORATION 2 Section 2.1. Governing Documents 2 Secti
June 16, 2021	EX-99.1	Elanco Announces Agreement to Acquire Kindred Biosciences Bolt-on Acquisition Accelerates Elanco’s Expansion in Pet Health Elanco to host conference call for investment community at 8:00 am Eastern Time Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga, 302-897-0668, [email protected] Media Contact: Colleen Parr Dekker, 317-989-7011, [email protected] For KindredBio: Katja Buhrer, 917-969-3438, [email protected] Elanco Announces Agreement to Acquire Kindred Biosciences Bolt-on Acquisition
June 16, 2021	EX-99.2	Important Information 2 Important Information for Investors and Stockholders This presentation does not constitute a solicitation of any vote or approval in connection with the proposed acquisition of K ind red Biosciences, Inc. (“ KindredBio ”) by E Elanco Animal Health to Acquire June 16, 2021 Exhibit 99.2 Important Information 2 Important Information for Investors and Stockholders This presentation does not constitute a solicitation of any vote or approval in connection with the proposed acquisition of K ind red Biosciences, Inc. (? KindredBio ?) by Elanco Animal Health Incorporated (?Elanco? and such proposed acquisition, the ?Merger?). Ki
June 9, 2021	8-K	Material Impairments UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm
June 4, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm
June 4, 2021	EX-99.1	Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary Kirberger brings leadership experiences at both U.S. and German based companies to Elanco Exhibit 99.1 Investor Contact: Tiffany Kanaga, +1.302.897.0668 [email protected] Media Contact: Colleen Parr Dekker, +1.317.989.7011 [email protected] FOR IMMEDIATE RELEASE Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary Kirberger brings leadership experiences at both U.S. and German based companies to Elanco Greenfield, Ind. (June 4
May 25, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana (State or Other Jurisdiction of Incorporation) 2500 Innovation Way, Greenfield Indiana (Address of principal executive offices) 001-38661 (Commission File Number) 82-5497352 (I.R.S. Employer Id
May 21, 2021	EX-10.1	Amended and Restated 2018 Elanco Stock Plan (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on May 21, 2021). Exhibit 10.1 Amended and Restated 2018 Elanco Stock Plan ARTICLE 1. PURPOSES OF THE PLAN The Company previously adopted the 2018 Elanco Stock Plan, as amended from time to time, which was adopted by the Board of Directors on September 5, 2018 and approved by the shareholders of the Company on September 18, 2018. The Company hereby amends and restates the 2018 Elanco Stock Plan. The Company believe
May 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Comm
May 7, 2021	EX-10.2	Form of Elanco Animal Health Incorporated Performance-Based Restricted Stock Unit Award Agreement for executives with respect to annual awards (filed herewith). EXHIBIT 10.2 Elanco Animal Health Incorporated Performance-Based Award Agreement This Performance-Based Award is granted on , 2021 (?Grant Date?), by Elanco Animal Health Incorporated, an Indiana corporation (?Elanco? or the ?Company?), to the Eligible Individual who has received this Performance-Based Award Agreement (the ?Grantee?). Number of Shares: Log into UBS account at http://equity.elancod
May 7, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi
May 7, 2021	10-Q	Quarterly Report - 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? Transition Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 COMMISSION FILE NUMBER 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in
May 7, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (Commi
May 7, 2021	EX-10.3	Elanco Animal Health Incorporated Corporate Bonus Plan (filed herewith). EX-10.3 4 ex1032021elancocorporatebo.htm EX-10.3 EXHIBIT 10.3 The Elanco Corporate Bonus Plan (as amended effective January 1, 2021) As Amended Effective January 1, 2021 TABLE OF CONTENTS SECTION 1. PURPOSE 1 SECTION 2. DEFINITIONS 1 SECTION 3. ADMINISTRATION 5 SECTION 4. PARTICIPATION IN THE PLAN 6 SECTION 5. DEFINITION AND COMPUTATION OF COMPANY BONUS 7 SECTION 6. TIME OF PAYMENT 11 SECTION 7. A
May 7, 2021	EX-99.1	Elanco Animal Health Reports First Quarter 2021 Results Exceeded first quarter 2021 guidance; Updating full year 2021 guidance, raising and tightening adjusted ranges Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports First Quarter 2021 Results Exceeded first quarter 2021 guidance; Updating full year 2021 guidance, raising and tightening adjusted ranges ? Revenue in the first quarter was $1,
May 7, 2021	EX-10.1	Form of Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement for executives with respect to annual awards (filed herewith). EXHIBIT 10.1 Elanco Animal Health Incorporated Restricted Stock Unit Award Agreement This Restricted Stock Unit Award is granted on , 2021 (?Grant Date?) by Elanco Animal Health Incorporated, an Indiana corporation (?Elanco? or the ?Company?), to the Eligible Individual who has received this Restricted Stock Unit Award Agreement (the ?Grantee?). Number of Shares: Log into UBS account at http://equ
April 8, 2021	DEFA14A	- DEFA14A DEFA14A 1 nc10021857x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
March 25, 2021	DEF 14A	definitive proxy statement dated March 25, 2021, and filed with the Securities and Exchange Commission on March 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 1, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission file number 001-38661 Elanco Animal Health Incorporated (Exact name of Registrant as specified in its charter) INDIANA 82-5497352 (State or other jurisdiction of (I.R.S. Employer incor
March 1, 2021	EX-21.1	SUBSIDIARIES OF THE COMPANY SUBSIDIARIES OF THE COMPANY EXHIBIT 21.1 The following is a list of subsidiaries of the company as of December 31, 2020, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. Subsidiary Name Jurisdiction Aratana Therapeutics, Inc. United States ChemGen Corporation Massachusetts Dista Products Limited United Kingdom Elanco (Shanghai) Animal He
March 1, 2021	EX-10.31	Elanco Executive Severance Pay Plan and Summary EXHIBIT 10.31 Elanco Executive Severance Pay Plan and Summary Introduction The Elanco Executive Severance Pay Plan and Summary ("Plan") effective as of , 2020, defines those circumstances under which Elanco US Inc. and Lohmann Animal Health International, Inc. (collectively, "Elanco" or the "Company") may provide severance benefits to you in the event your employment with Elanco is terminated unde
February 24, 2021	EX-99.1	Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (302) 897-0668 or [email protected] Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] Elanco Animal Health Reports Fourth Quarter and Full Year 2020 Results ? Fourth quarter 2020 revenue was $1,139.7 million, growth of 45 percent, comprised of $743.4 million from the legacy Elanco portfolio a
February 24, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
February 23, 2021	EX-99.1	Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media: Colleen Parr Dekker +1.317.989.7011 [email protected] Investor Relations: Tiffany Kanaga +1.302.897.0668 [email protected] Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion GREENFIELD, Ind. (February 22, 2021) Ela
February 23, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)
February 12, 2021	SC 13G/A	SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Elanco Animal Health Inc. (Name of Issuer) (Title of Class of Securities) (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Elanco Animal Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 28414H103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 3, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Elanco Animal Health Inc (Name of Issuer) Common Stock (Title of Class of Securities) 28414H103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 2, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Elan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Elanco Animal Health Incorporated (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 28414H103 (CUSIP Number) Michelle Gosom Arist
January 26, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 25, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 26, 2021	EX-99.1	Elanco Announces Next Wave of Restructuring to Drive Operational Efficiencies Post Bayer Acquisition Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 DRAFT FOR REVIEW ONLY Media: Colleen Parr Dekker +1.317.989.7011 [email protected] Investor Relations: Tiffany Kanaga +1.302.897.0668 [email protected] Elanco Announces Next Wave of Restructuring to Drive Operational Efficiencies Post Bayer Acquisition · Actions are expected to generate approximately $20-2
January 11, 2021	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2021 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation) (
January 11, 2021	EX-99.1	Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart Transformation efforts will streamline and localize as next phase of integration is realized Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Media Contact: Colleen Parr Dekker +1 (317) 989.7011 or [email protected] Investor Contact: Tiffany Kanaga +1 (302) 897.0668 or [email protected] Elanco Begins Next Phase of Integration Post-Bayer Animal Health Acquisition; Executive Committee Member Sarena Lin to Depart Transformatio
December 17, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2020 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdiction of incorporation)

ELAN / Elanco Animal Health Incorporated - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings

MX:ELAN
DE:5EA	€ 14.78